The role of biologic agents in damage progression in rheumatoid arthritis: Indirect comparison of data coming from randomized clinical trials

Therapeutic Advances in Musculoskeletal Disease

Volumn 4, Issue 4, 2012, Pages 213-223

  Favalli, Ennio Giulio ^a   Pregnolato, Francesca ^b   Biggioggero, Martina ^a   Meroni, Pier Luigi ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

biologic therapy; metaanalysis; radiographic progression; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO;

ADULT; ARTICLE; CAUSAL ATTRIBUTION; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; DATA ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84868667029     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X12449082     Document Type: Article

References (26)

1. Breedveld F.C. Weisman M.H. Kavanaugh A.F. Cohen S.B. Pavelka K. Vollenhoven R.V. et al. for the G.T.PREMIER Investigators (2005) The PREMIER study: A multicenter, randomised, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26–37.
2. Courvoisier N. Dougados M. Cantagrel A. Goupille P. Meyer O. Sibilia J. et al. (2008) Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther 10 (5): R106.
3. Elbourne D.R. Altman D.G. Higgins J.P.T. Curtin F. Worthington H.V. Vail A. (2002) Meta-analyses involving cross-over trials: methodological issues. Intern J Epidemiol 31: 140–149.
4. Emery P. Durez P. Dougados M. Legerton C.W. Becker J.-C. Vratsanos G. et al. (2010) Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 69: 510–516.
5. Emery P. Fleischmann R. van der Heijde D. Keystone E.C. Genovese M.C. Conaghan P.G. et al. (2011) The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomised controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 63: 1200–1210.
6. Genant H.K. (1983) Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 75(6A): 35–47.
7. Genovese M.C. Bathon J.M. Martin R.W. Fleischmann R.M. Tesser J.R. Schiff M.H. et al. (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46: 1443–1450.
8. Goekoop-Ruiterman Y.P.M. de Vries-Bouwstra J.K. Allaart C.F. van Zeben D. Kerstens P.J.S.M. Hazes J.M.W. et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomised, controlled trial. Arthritis Rheum 52: 3381–3390.
9. Irwig L. Tosteson A.N. Gatsonis C. Lau J. Colditz G. Chalmers T.C. et al. (1994) Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med 120: 667–676.
10. Keystone E. Heijde D.V.D. Mason D. Jr Landewé R. Vollenhoven R.V. Combe B. et al. (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomised, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58: 3319–3329.
11. Keystone E.C. Kavanaugh A.F. Sharp J.T. Tannenbaum H. Hua Y. Teoh L.S. et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomised, placebo-controlled, 52-week trial. Arthritis Rheum 50: 1400–1411.
12. Klareskog L. van der Heijde D. de Jager J.P. Gough A. Kalden J. Malaise M. et al., for the M.TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675–681.
13. Korpela M. Laasonen L. Hannonen P. Kautiainen H. Leirisalo-Repo M. Hakala M. et al. for the T.FIN-RACo Trial Group (2004) Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: Five-year experience from the FIN-RACo study. Arthritis Rheum 50: 2072–2081.
14. Kremer J.M. Genant H.K. Moreland L.W. Russell A.S. Emery P. Abud-Mendoza C. et al. (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomised trial. Ann Intern Med 144: 865–876.
15. Kremer J.M. Russell A.S. Emery P. Abud-Mendoza C. Szechinski J. Westhovens R. et al. (2011) Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 70: 1826–1830.
16. Landewé R. Boers M. Verhoeven A.C. Westhovens R. van de Laar M.A.F.J. Markusse H.M. et al. (2002) COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 46: 347–356.
17. Lassere M. (2000) Pooled metaanalysis of radiographic progression: comparison of Sharp and Larsen methods. J Rheumatol 27: 269–275; discussion 276.
18. Lassere M.N. van der Heijde D. Johnson K. Bruynesteyn K. Molenaar E. Boonen A. et al. (2001) Robustness and generalizability of smallest detectable difference in radiological progression. J Rheumatol 28: 911–913.
19. Lipsky P.E. van der Heijde D.M. Clair E.W.S. Furst D.E. Breedveld F.C. Kalden J.R. et al. for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343: 1594–1602.
20. Normand S.L. (1999) Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 18: 321–359.
21. Peterfy C.G. Wu C. Szechinski J. DiCarlo J.C. Lu Y. Genovese M. et al. (2011) Comparison of the Genant-modified Sharp and van der Heijde-modified Sharp scoring methods for radiographic assessment in rheumatoid arthritis. Intern J Clin Rheumatol 6: 15–24.
22. Sharp J.T. Lidsky M.D. Collins L.C. Moreland J. (1971) Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 14: 706–720.
23. Sharp J.T. Wolfe F. Lassere M. Boers M. van der Heijde D. Larsen A. et al. (2004) Variability of precision in scoring radiographic abnormalities in rheumatoid arthritis by experienced readers. J Rheumatol 31: 1062–1072.
24. Smolen J.S. Landewe R. Breedveld F.C. Dougados M. Emery P. Gaujoux-Viala C. et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69: 964–975.
25. St Clair E.W. van der Heijde D.S.E.M.F.M. Smolen J.S. Maini R.N. Bathon J.M. Emery P. et al. for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomised, controlled trial. Arthritis Rheum 50: 3432–3443.
26. van der Heijde D. (2000) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27: 261–263.